A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Telmione plus 80/12.5mg
Micardis plus 80/12.5mg
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Healthy adult volunteers aged ≥ 19 years at screening
- Body weight ≥ 50kg and Body mass index (BMI) in the range of 18.0 and 30.0 kg/㎡
- Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings as a result of physical examination
- Determined by the investigator to be eligible for study participation based on the results of screening tests (clinical laboratory tests, vital signs, physical examination, 12-lead ECG) conducted according to the IP characteristics
- Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding
Exclusion Criteria:
- Subjects with a presence and a history of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal disease
- Pregnant(positive urine HCG) or breastfeeding women if female
- Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Subjects with a presence and a history of surgery or gastrointestinal diseases which might significantly change absorption of medicines
- Subjects with hypersensitivity or a history of clinically significant hyper sensitivity to ingredients with IPs, excipients, other drugs including sulfonamide and renin-angiotensin class
Subjects with the following results in clinical laboratory tests
- AST/ALT/ALP/γ-GTP/Bilirubin total > UNL (upper normal limit) × 2
- Creatinine in plasma which is outside the accepted normal range or eGFR calculated by MDRD < 60 mL/min/1.73 ㎡
- CK > UNL × 2
- Subjects with a history of drug abuse or positive to drug abuse at urine drug screening test
- Subjects with systolic blood pressure (SBP) ≥ 140 mmHg or ≤ 90 mmHg, diastolic blood pressure (DBP) ≥ 100 mmHg or ≤ 60 mmHg, or pulse rate (PR) ≤ 40 bpm or ≥ 100 bpm on vital signs measured in sitting position after taking a rest for at least 3 minutes during screening test
Subjects with clinically significant opinions including the following results in 12-lead ECG test during screening test
- QTc > 450 ms
- PR interval > 200 ms
- QRS duration > 120 ms
- Subjects who have an abnormal diet that can affect ADME of drugs or consume foods that can affect drug metabolism
- Subjects who have taken any prescription drugs or herbal medicine within 2 weeks prior to the 1st IP administration, or any over-the-counter (OTC) drug, health functional food or vitamin preparation within 10 days to the 1st IP administration (However, can participate in the study if otherwise eligible in the judgment of the investigator)
- Subjects who have taken the drug which can induce or inhibit drug metabolism enzyme within 1 month prior to the 1st IP administration
- Subjects who have participated in any other clinical study or bioequivalnece study within 6 months prior to the 1st IP administration(However, the criterion for termination of participation in other clinical study or bioequivalence study is the last administration date, and the next day is counted as one day.)
- Subjects who have donated whole blood within 2 months prior to the 1st IP administration or have donated blood components or received transfusion within 1 month prior to the 1st IP administration
Subject who have continued drink of alcohol (> 21 units/week, 1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the 1st IP administration or are unable to stop drinking from the time of signing the informed consent form to post study visit
- alcohol (g) = intake volume(mL) × level(%) × 0.8
- Subject who have a history of excessive smoking (> 10 cigarettes/day) within 3 months prior to the 1st IP administration and unable to stop smoking from 24 hours before the administration at each period to the last sampling time at each period
- Subjects who take or are unable to stop foods containing grapefruit from 48 hours before the 1st IP administration to post study visit
- Subject who take or are unable to stop foods containing caffeine(coffee, green tea, black tee, soda, coffee-flavored milk, nutritive tonic drink) from 24 hours before the administration at each period to the last sampling time at each period
- Subjects who have exercised vigorously exceeding the level of daily life during the period from 48 hours before the 1st administration to post study visit, or who are unable to stop vigorous exercise
- Subjects or their spouse or partner who are not using an approved method of contraception or even if are not planning to become pregnant (e.g., contraceptive administration and implantation, intrauterine device, Those who are not using procedures (vasectomy, tubal ligation, etc.) from the time of written consent of the subject until two weeks after the last bioequivalence study drug administration date
- Subjects who have determined that the investigator is unsuitable to participate in the bioequivalence test due to reasons other than the above selection/exclusion criteria
Sites / Locations
- Chungbuk National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Sequence A
Sequence B
Arm Description
TRTR
RTRT
Outcomes
Primary Outcome Measures
Cmax of telmisartan
AUClast of telmisartan
Cmax of hydrochlorothiazide
AUClast of hydrochlorothiazide
Secondary Outcome Measures
Tmax of telmisartan
AUCinf of telmisartan
t1/2 of telmisartan
CL/F of telmisartan
Vd/F of telmisartan
Tmax of hydrochlorothiazide
AUCinf of hydrochlorothiazide
t1/2 of hydrochlorothiazide
CL/F of hydrochlorothiazide
Vd/F of hydrochlorothiazide
Full Information
NCT ID
NCT05040880
First Posted
August 25, 2021
Last Updated
February 14, 2022
Sponsor
HK inno.N Corporation
1. Study Identification
Unique Protocol Identification Number
NCT05040880
Brief Title
A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers
Official Title
A Bioequivalence Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Administration of TELMIONE PLUS TAB. 80/12.5mg and MICARDIS PLUS TAB. 80/12.5mg in Healthy Adult Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
July 8, 2021 (Actual)
Primary Completion Date
October 31, 2021 (Actual)
Study Completion Date
October 31, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
HK inno.N Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To compare the pharmacokinetics and safety after a single dose administration of Telmione plus® 80/12.5mg and Micardis plus® 80/12.5mg in healthy adult volunteers
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sequence A
Arm Type
Experimental
Arm Description
TRTR
Arm Title
Sequence B
Arm Type
Experimental
Arm Description
RTRT
Intervention Type
Drug
Intervention Name(s)
Telmione plus 80/12.5mg
Intervention Description
Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Intervention Type
Drug
Intervention Name(s)
Micardis plus 80/12.5mg
Intervention Description
Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Primary Outcome Measure Information:
Title
Cmax of telmisartan
Time Frame
Up to 72 hours
Title
AUClast of telmisartan
Time Frame
Up to 72 hours
Title
Cmax of hydrochlorothiazide
Time Frame
Up to 72 hours
Title
AUClast of hydrochlorothiazide
Time Frame
Up to 72 hours
Secondary Outcome Measure Information:
Title
Tmax of telmisartan
Time Frame
Up to 72 hours
Title
AUCinf of telmisartan
Time Frame
Up to 72 hours
Title
t1/2 of telmisartan
Time Frame
Up to 72 hours
Title
CL/F of telmisartan
Time Frame
Up to 72 hours
Title
Vd/F of telmisartan
Time Frame
Up to 72 hours
Title
Tmax of hydrochlorothiazide
Time Frame
Up to 72 hours
Title
AUCinf of hydrochlorothiazide
Time Frame
Up to 72 hours
Title
t1/2 of hydrochlorothiazide
Time Frame
Up to 72 hours
Title
CL/F of hydrochlorothiazide
Time Frame
Up to 72 hours
Title
Vd/F of hydrochlorothiazide
Time Frame
Up to 72 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy adult volunteers aged ≥ 19 years at screening
Body weight ≥ 50kg and Body mass index (BMI) in the range of 18.0 and 30.0 kg/㎡
Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings as a result of physical examination
Determined by the investigator to be eligible for study participation based on the results of screening tests (clinical laboratory tests, vital signs, physical examination, 12-lead ECG) conducted according to the IP characteristics
Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding
Exclusion Criteria:
Subjects with a presence and a history of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal disease
Pregnant(positive urine HCG) or breastfeeding women if female
Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Subjects with a presence and a history of surgery or gastrointestinal diseases which might significantly change absorption of medicines
Subjects with hypersensitivity or a history of clinically significant hyper sensitivity to ingredients with IPs, excipients, other drugs including sulfonamide and renin-angiotensin class
Subjects with the following results in clinical laboratory tests
AST/ALT/ALP/γ-GTP/Bilirubin total > UNL (upper normal limit) × 2
Creatinine in plasma which is outside the accepted normal range or eGFR calculated by MDRD < 60 mL/min/1.73 ㎡
CK > UNL × 2
Subjects with a history of drug abuse or positive to drug abuse at urine drug screening test
Subjects with systolic blood pressure (SBP) ≥ 140 mmHg or ≤ 90 mmHg, diastolic blood pressure (DBP) ≥ 100 mmHg or ≤ 60 mmHg, or pulse rate (PR) ≤ 40 bpm or ≥ 100 bpm on vital signs measured in sitting position after taking a rest for at least 3 minutes during screening test
Subjects with clinically significant opinions including the following results in 12-lead ECG test during screening test
QTc > 450 ms
PR interval > 200 ms
QRS duration > 120 ms
Subjects who have an abnormal diet that can affect ADME of drugs or consume foods that can affect drug metabolism
Subjects who have taken any prescription drugs or herbal medicine within 2 weeks prior to the 1st IP administration, or any over-the-counter (OTC) drug, health functional food or vitamin preparation within 10 days to the 1st IP administration (However, can participate in the study if otherwise eligible in the judgment of the investigator)
Subjects who have taken the drug which can induce or inhibit drug metabolism enzyme within 1 month prior to the 1st IP administration
Subjects who have participated in any other clinical study or bioequivalnece study within 6 months prior to the 1st IP administration(However, the criterion for termination of participation in other clinical study or bioequivalence study is the last administration date, and the next day is counted as one day.)
Subjects who have donated whole blood within 2 months prior to the 1st IP administration or have donated blood components or received transfusion within 1 month prior to the 1st IP administration
Subject who have continued drink of alcohol (> 21 units/week, 1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the 1st IP administration or are unable to stop drinking from the time of signing the informed consent form to post study visit
alcohol (g) = intake volume(mL) × level(%) × 0.8
Subject who have a history of excessive smoking (> 10 cigarettes/day) within 3 months prior to the 1st IP administration and unable to stop smoking from 24 hours before the administration at each period to the last sampling time at each period
Subjects who take or are unable to stop foods containing grapefruit from 48 hours before the 1st IP administration to post study visit
Subject who take or are unable to stop foods containing caffeine(coffee, green tea, black tee, soda, coffee-flavored milk, nutritive tonic drink) from 24 hours before the administration at each period to the last sampling time at each period
Subjects who have exercised vigorously exceeding the level of daily life during the period from 48 hours before the 1st administration to post study visit, or who are unable to stop vigorous exercise
Subjects or their spouse or partner who are not using an approved method of contraception or even if are not planning to become pregnant (e.g., contraceptive administration and implantation, intrauterine device, Those who are not using procedures (vasectomy, tubal ligation, etc.) from the time of written consent of the subject until two weeks after the last bioequivalence study drug administration date
Subjects who have determined that the investigator is unsuitable to participate in the bioequivalence test due to reasons other than the above selection/exclusion criteria
Facility Information:
Facility Name
Chungbuk National University Hospital
City
Cheongju-si
State/Province
Chungcheongbuk-do
ZIP/Postal Code
28644
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers
We'll reach out to this number within 24 hrs